Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients

NCT04409522 is registered in ClinicalTrials.gov with Mohammad Sadegh Bagheri Baghdasht as lead sponsor.

NCT NCT04409522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04409522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients
Lead sponsor
Mohammad Sadegh Bagheri Baghdasht
Phase
Not applicable
Overall status
Unknown status
Start date
May 12, 2020
Completion date
September 25, 2020
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19